Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification

被引:24
作者
Furukawa, Kenei [1 ]
Shiba, Hiroaki [1 ]
Horiuchi, Takashi [1 ]
Shirai, Yoshihiro [1 ]
Haruki, Koichiro [1 ]
Fujiwara, Yuki [1 ]
Sakamoto, Taro [1 ]
Gocho, Takeshi [1 ]
Yanaga, Katsuhiko [1 ]
机构
[1] Jikei Univ, Sch Med, Dept Surg, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan
关键词
Barcelona Clinic Liver Cancer classification; Hepatic resection; Hepatocellular carcinoma; STAGING SYSTEMS; VALIDATION; BCLC;
D O I
10.1002/jhbp.436
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundThe Barcelona Clinic Liver Cancer (BCLC) classification is the most widely used staging system for hepatocellular carcinoma (HCC), but its prognostic ability in patients after resection has not been yet validated. The aim of this study was to evaluate the BCLC classification among patients after resection. MethodsThe subjects were 196 patients who underwent hepatic resection for HCC between April 2003 and December 2014 at Jikei University Hospital. All patients were classified into a tumor stage according to the BCLC classification. Overall survival rate was calculated according to stages defined by the BCLC classification. ResultsOverall survival rates at 1, 3 and 5-year were 100%, 95.2% and 95.2% in BCLC 0, 96.7%, 90.0% and 78.4% in BCLC A solitary, 86.2%, 86.2% and 86.2% in BCLC A multiple, 100.0%, 78.8% and 78.8% in BCLC B and 86.5%, 63.3% and 57.6% in BCLC C, respectively. Postoperative complications and mortality rates in relation to BCLC stage were comparable. ConclusionThe BCLC treatment algorithm should consider the role of resection also for multiple early, intermediate and advanced stages.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 18 条
[1]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[2]   Hepatocellular carcinoma: clinical frontiers and perspectives [J].
Bruix, Jordi ;
Gores, Gregory J. ;
Mazzaferro, Vincenzo .
GUT, 2014, 63 (05) :844-855
[3]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[4]   Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population [J].
Chan, Stephen L. ;
Mo, Frankie K. F. ;
Johnson, Philip J. ;
Liem, Giok S. ;
Chan, Tung C. ;
Poon, Ming C. ;
Ma, Brigette B. Y. ;
Leung, Thomas W. T. ;
Lai, Paul B. S. ;
Chan, Anthony T. C. ;
Mok, Tony S. K. ;
Yeo, Winnie .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 (02) :340-347
[5]  
European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]
[6]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Llovet, Josep M. ;
Bruix, Jordi .
LANCET, 2012, 379 (9822) :1245-1255
[7]   The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? [J].
Kim, Kwang Min ;
Sinn, Dong Hyun ;
Jung, Sin-Ho ;
Gwak, Geum-Youn ;
Paik, Yong-Han ;
Choi, Moon Seok ;
Lee, Joon Hyeok ;
Koh, Kwang Cheol ;
Paik, Seung Woon .
LIVER INTERNATIONAL, 2016, 36 (10) :1490-1497
[8]   Liver Cancer Working Group Report [J].
Kudo, Masatoshi ;
Han, Kwang Hyub ;
Kokudo, Norihiro ;
Cheng, Ann-Lii ;
Choi, Byung Ihn ;
Furuse, Junji ;
Izumi, Namiki ;
Park, Joong-Won ;
Poon, Ronnie T. ;
Sakamoto, Michiie .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 :i19-i27
[9]   Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model [J].
Liu, Po-Hong ;
Hsu, Chia-Yang ;
Hsia, Cheng-Yuan ;
Lee, Yun-Hsuan ;
Huang, Yi-Hsiang ;
Chiou, Yi-You ;
Lin, Han-Chieh ;
Huo, Teh-Ia .
ANNALS OF SURGERY, 2016, 263 (03) :538-545
[10]   Prognosis of hepatocellular carcinoma:: The BCLC staging classification [J].
Llovet, JM ;
Brú, C ;
Bruix, J .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :329-338